7.7. primary treatment disease type. type therapy turb based risk groups shown section 6.3 table 6.1. stratification treatment recommendations primarily based risk disease progression (table 6.2). instances, mainly intermediate-risk tumours, 2006 eortc scoring model useful (section 6.1.1.1) determine patient’s individual risk disease recurrence basis decide treatment on. treatment low-risk disease patients low-risk group negligible risk disease progression. single post-operative instillation chemotherapy reduces risk recurrence considered sufficient treatment patients. treatment intermediate-risk disease patients intermediate-risk group relatively low risk disease progression (7.4 8.5% 10 years according 2021 eau nmibc scoring model). patients induction chemotherapy without maintenance maximum one year reasonable first-line option majority patients. one-year full-dose bcg treatment (induction plus 3-weekly instillations 3, 6 12 months), alternative option. final choice reflect individual patient’s risk recurrence progression well efficacy side effects treatment modality. treatment high-risk disease patients high-risk group high risk disease progression (14% 10 years according 2021 eau nmibc scoring model). patients full-dose intravesical bcg one 3 years (induction plus 3-weekly instillations 3, 6, 12, 18, 24, 30 36 months), indicated. additional beneficial effect second third years maintenance weighed added costs, side effects problems associated bcg shortage. high risk progression, immediate rc may also discussed patient. radical cystectomy safest approach oncological point view, is, however, associated risk complications qol impairment represents over-treatment patients. treatment high-risk disease patients high-risk group extremely high risk tumour progression (53.1 58.6% 10 years according 2021 eau nmibc scoring model). immediate rc discussed patients. case rc feasible refused patient, full-dose intravesical bcg one 3 years offered. treatment carcinoma situ patients carcinoma situ cannot managed endoscopic procedure alone offered either intravesical bcg instillations rc. bcg treatment cis increases complete response rate, overall percentage patients remain disease free, reduces risk tumour progression. comparison, immediate rc cis results excellent tumour-specific survival rates although large proportion patients might over-treated .